Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

Inclusion Criteria

• Participant is healthy, aged between 8 months (± 2 weeks) at inclusion visit
• Subject is a full-term infant
• Subject's parents or legal guardian willing to provide signed informed consent.
• Children have completed 3 doses each of diphtheria, tetanus, pertussis (DTP) and oral polio vaccine (OPV).

Exclusion Criteria

• History of documented HIV.
• Known or suspected impairment of immunologic function.
• History of serious chronic disease
• Underlying medical condition such as inborn errors of metabolism, failure to thrive, bronchopulmonary dysplasia, or any major congenital abnormalities requiring surgery or chronic treatment.
• Acute medical illness with or without fever within the last 72 hours or an axillary temperature ≥ 37.5°C at the time of inclusion.
• History of documented suspected encephalitis, encephalopathy, or meningitis
• History of measles
• History of thrombocytopenic purpura.
• Received any JE or measles vaccine prior to enrollment.
• Received any vaccine, other than the study vaccines, within 2 weeks prior to or scheduled to receive a non-study vaccination during the conduct of this trial.
• Hypotonic - hyporesponsiveness, after the preceding vaccination.
• History of seizures, including history of febrile seizures, or any other neurologic disorder.
• Prior or anticipated receipt of immune globulin or other blood products, or injected or oral corticosteroids or other immune modulator therapy except routine vaccines within 6 weeks of administration of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting 3 hours) observed after a previous dose.
• Unable to attend the scheduled visits or comply with the study procedures.
• Enrolled in another clinical trial involving any therapy.
• Any condition that in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the study objectives.